Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Executive Summary
Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.